Rigel Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

FAIR VALUE (Tables)

FAIR VALUE (Tables)

12 Months Ended

Dec. 31, 2018

Schedule of financial assets measured at fair value on a recurring basis

Financial assets measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations (in thousands):


	Assets at Fair Value as of December 31, 2018
	Level 1		Level 2		Level 3		Total
Money market funds	$	9,106	$	—	$	—	$	9,106
Government-sponsored enterprise securities		—		7,872		—		7,872
Corporate bonds and commercial paper		—		108,933		—		108,933
Total	$	9,106	$	116,805	$	—	$	125,911


	Assets at Fair Value as of December 31, 2017
	Level 1		Level 2		Level 3		Total
Money market funds	$	2,795	$	—	$	—	$	2,795
U.S. treasury bills		—		6,726		—		6,726
Government-sponsored enterprise securities		—		7,826		—		7,826
Corporate bonds and commercial paper		—		97,822		—		97,822
Total	$	2,795	$	112,374	$	—	$	115,169